By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Therapeutics Appoints Adam E. Allgood, Pharm.D., R.Ph., As Executive Director Of Clinical Development 7/16/2015 7:39:04 AM
Galectin Therapeutics Initiates Enrollment For GR-MD-02 Phase II Clinical Trial In NASH With Cirrhosis 6/29/2015 7:27:47 AM
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director 6/3/2015 7:35:37 AM
Galectin Therapeutics To Present At LD Micro Invitational Conference 5/28/2015 7:51:24 AM
Galectin Therapeutics To Webcast Corporate Update Following Annual Meeting Of Stockholders 5/15/2015 10:16:56 AM
Galectin Therapeutics Reports No Drug-Drug Interaction Between GR-MD-02 And Midazolam 5/14/2015 1:30:17 PM
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase II Nash Program 5/11/2015 7:46:01 AM
Galectin Therapeutics Presented Research With GR-MD-02 At The American Association for Study of Liver Diseases Industry Colloquium 3/24/2015 10:24:19 AM
Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update 3/19/2015 7:56:17 AM
Galectin Therapeutics Engages PPD, Inc. (PPDI) To Conduct GR-MD-02 Phase 2 Trial In NASH, Submits Special Protocol Assessment To FDA 3/12/2015 7:17:30 AM